Is COGNITION THERAPEUTICS INC (CGTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.9% / 30% | 27.5% / 30% | 3.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.9% / 33% | 27.5% / 33% | 3.0% / 33% | N/A | ✓ HALAL |
| MSCI | 2.7% / 33% | 82.7% / 33% | 8.9% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.9% / 33% | 27.5% / 33% | 3.0% / 33% | N/A | ✓ HALAL |
| FTSE | 2.7% / 33% | 82.7% / 33% | 8.9% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -88.6% | |
| Return on Assets (ROA) | -76.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$28M |
| Free Cash Flow | -$28M |
| Total Debt | $814,000 |
| Debt-to-Equity | 1.0 |
| Current Ratio | 3.4 |
| Total Assets | $30M |
Price & Trading
| Last Close | $1.08 |
| 50-Day MA | $1.13 |
| 200-Day MA | $1.32 |
| Avg Volume | 812K |
|
52-Week Range
$0.22
| |
About COGNITION THERAPEUTICS INC (CGTX)
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is COGNITION THERAPEUTICS INC (CGTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), COGNITION THERAPEUTICS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is COGNITION THERAPEUTICS INC's debt ratio?
COGNITION THERAPEUTICS INC's debt ratio is 0.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.7%.
What are COGNITION THERAPEUTICS INC's key financial metrics?
COGNITION THERAPEUTICS INC has a market capitalization of $65M. Return on equity stands at -88.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.